[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pompe-disease-late-onset\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pompe-disease-late-onset":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,56,85,130,152,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100614688","phase-1-a-study-to-evaluate-safety-tolerability-and-efficacy-of-ab-1009-gene-therapy-gaa-gene-in-adult-participants-with-late-onset-pompe-disease-progress-gt-lopd-100614688",false,"NCT07282847","A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)","A Single-Arm, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability and Efficacy of a Single Intravenous Infusion of AB-1009 in Adult Participants With Late Onset Pompe Disease (LOPD)","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age at the time of signing the informed consent form.\n2. Confirmed GAA enzyme deficiency from any tissue source and\u002For confirmed biallelic GAA gene mutations.\n3. Undergone enzyme replacement treatment (ERT) (either alglucosidase alfa (Lumizyme®) or avalglucosidase alfa-ngpt (Nexviazyme®)), for at least 6 months (at least 10 infusions) before signing the initial informed consent form. During the screening process, participants need to remain on their current ERT until close to dosing;\n4. FVC in the upright position ≥30% and ≤80% of predicted;\n5. Capable of walking at least 100 meters in the 6MWT (use of a cane, quad cane, or standard walker is permitted);\n6. Contraceptive\u002Fbarrier use by men and women requirements as per protocol.\n7. Capable of giving informed consent and able to understand and comply with all study procedures.\n\nExclusion Criteria:\n\n1. Severe cardiomyopathy, defined as left ventricular ejection fraction (LVEF) \\\u003C40% or New York Heart Association (NYHA) functional class 3 or above;\n2. Require invasive mechanical ventilation, or rely on noninvasive ventilation during the day;\n3. Intolerance to ERT or investigator-assessed intolerance to ERT, prior experience of serious ERT-related infusion-associated reactions (IARs);\n4. Have known intrinsic liver diseases, including hepatitis, HIV-related liver disease, prior diagnosis of portal hypertension, splenomegaly, hepatic encephalopathy, severe fatty liver, cirrhosis or liver fibrosis ≥stage 2, ultrasound-identified liver neoplasms, or laboratory tests suggesting elevated alpha-fetoprotein. Patients with liver function tests including ALT or AST \\>3× upper limit of normal (ULN) or any total bilirubin above ULN during screening will also be excluded;\n5. Prior or ongoing medical condition(s), physical finding(s), assessment findings, or laboratory abnormality that, in the investigator's opinion, would impact participant's safety and compliance with the study procedures.\n6. Have received gene therapy prior to screening;\n7. Have received any systemic immunosuppressants (except inhalation or topical use) other than glucocorticoids or investigator-recommended immunosuppressants 30 days prior to screening through completion of screening, and\u002For known intolerance to immunosuppressants such as glucocorticoids;\n8. Use of investigational drugs or drugs that could affect this study as evaluated by the investigator within 30 days prior to screening through completion of Week 52 or within 5 half-lives of the investigational drug (whichever is longer);\n9. Have received any vaccine within 30 days prior to dosing;\n10. Other conditions that make the participant not eligible for the study according to the investigator.","ALL","18 Years",{"count":19,"type":20},12,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability and efficacy of a single intravenous infusion of AB-1009 in adult participants with late-onset Pompe disease (LOPD).",[27,28,29],"Pompe Disease (Late-onset)","Pompe Disease Late-Onset","LOPD",[31,32,33,34,35,36,37,38,29,39,40,41,42],"Pompe Disease","Glycogen Storage Disease","Lysosomal Storage Diseases","Acid Maltase Deficiency","Acid Maltase Deficiency Disease","Gene Therapy","AB-1009","Neuromuscular Disease","Acid-Alpha Glucoside (GAA)","GAA gene","Adeno-Associated Virus (AAV)","Late-Onset Pompe Disease","RECRUITING","2026-05-27",{"date":46,"type":47},"2026-05-28","ACTUAL",{"date":49,"type":47},"2026-04-15",{"date":51,"type":20},"2032-09",{"name":53,"class":54},"AskBio Inc","INDUSTRY",9,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":63,"minAge":4,"maxAge":4,"enrollmentInfo":64,"targetDuration":66,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100100246","pompe-pregnancy-sub-registry-100100246","NCT00567073","Pompe Pregnancy Sub-Registry","A Sub-registry to Observe the Effect of Alglucosidase Alfa or Avalglucosidase Alfa Treatment on Pregnancy and Infant Growth in Women With Pompe Disease","Inclusion Criteria:\n\nEligible women must:\n\n* be enrolled in the Pompe registry (NCT00231400)\n* be pregnant, or have been pregnant with appropriate medical documentation available.\n* provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed.\n\nNote: It is recommended that pregnancy data be collected on eligible women regardless of infant enrollment. In the event of patients having multiple pregnancies, participation in this Sub-Registry is encouraged for each individual pregnancy.\n\nExclusion Criteria:\n\nThere are no exclusion criteria for this Sub-Registry","FEMALE",{"count":65,"type":20},20,"4 Years","OBSERVATIONAL","This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Pompe Registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglucosidase alfa or avalglucosidase alfa) and irrespective of the commercial product with which she may be treated. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.\n\nThe primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Pompe disease during pregnancy, regardless of whether they receive disease-specific therapy, such as ERT with alglucosidase alfa or avalglucosidase alfa.",[70,27,71],"Glycogen Storage Disease Type II (GSD-II)","Glycogenesis 2 Acid Maltase Deficiency",[70,73,31,74,35,75],"GSD-II","Pompe Disease (Late-Onset)","Glycogenosis II",{"date":77,"type":47},"2026-04-16",{"date":79,"type":47},"2007-06-18",{"date":81,"type":20},"2034-01-31",{"name":83,"class":54},"Genzyme, a Sanofi Company",35,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":94,"briefSummary":96,"conditions":97,"keywords":115,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100629707","effects-of-whole-body-electrical-muscle-stimulation-exercise-on-adults-with-neuromuscular-disease-100629707","NCT07478172","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults withNeuromuscular Disease","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with one or more of the following neuromuscular conditions: Amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscle atrophy, spinal muscular atrophy, postpolio syndrome, inclusion body myositis, pompedisease, fascioscapulohumeral muscular dystrophy, charcot marie tooth disease, chronic inflammatory demyelinating polyneuropathy, hereditary spastic paraplegia, myasthenia gravis, lambert-eaton myasthenic syndrome, postural orthostatic tachycardia syndrome, mitochondrial myopathy, nemaline myopathy, centronuclear myopathy, lumbar radiculopathy, non-specific low back pain.\n* Ability to stand for approximately 15 minutes continuously with or without an assistive device (i.e. the length of time to stand to take a shower, complete meal preparation, wait in line at the bank, etc.)\n* At least some anti-gravity strength in major muscle groups as assessed by manual muscle testing (i.e. 2+\u002F5 strength or better)\n* Medical clearance to participate in an exercise program\n* Ability to provide informed consent\n* Ability to conform to the requirements of the study (i.e. attendance at assessment and intervention visits, maintain current level of non-study physical activity for the duration of the study, no intention to relocate mid-study)\n\nExclusion Criteria:\n\n* Diagnosed with one of the following neuromuscular conditions: Becker's muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, myotonic dystrophy type 1 or 2, Freidrich's ataxia, any other NMD with known or suspected cardiac involvement or muscle fiber structural integrity defects.\n* Concurrent participation in another interventional research study\n* Unable to tolerate 15 minutes of continuous standing with or without an assistive device\n* Presence of a pacemaker, metal implants, or other implanted medical devices that could impact participant safety during WB-EMS intervention\n* Presence of cochlear implant, cortical stimulator, deep brain stimulator, ventriculoperitoneal shunt, recent skull defect, seizure in the past 12 months while taking anti-epilepsy medication, or previous serious adverse event with TMS, which could impact participant safety during TMS testing\n* Presence of unstable acute or chronic disease (i.e. renal failure, rheumatologic disease, cardia arrhythmia, neoplasm, uncontrolled hypertension)\n* Known pregnancy at time of screening; verbal screening will occur throughout the study.\n* Presence of a terminal disease (i.e. receiving hospice services)\n* Current or previous use of any drugs known to influence muscle mass or performance within 6 months; these may include but are not limited to anabolic steroids, IGF01, growth hormone, replacement androgen therapy, anti-androgen therapy\n* Presence of an additional neurologic conditions affecting somatosensory or motor function\u002Fcontrol (i.e. Parkinson's disease, Multiple Sclerosis, h\u002Fo stroke, TBI, SCI, ataxia, apraxia, hemiplegia, etc.)\n* Musculoskeletal condition or surgery in the past year that would confound results of exercise interventions (i.e. TKA, THA, RTC repair, spinal fusion)\n* Other medical conditions, signs, or symptoms that would interfere with study conductor interpretation of results as determined by an investigator",{"count":93,"type":20},50,[95],"NA","This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions. Up to 50 adults with conditions like ALS, SMA, and MG will undergo 20-minute supervised WB-EMS sessions (1-2 times weekly for 4-8 weeks) using the Katalyst system. Outcomes include neural excitability (TMS), motor unit behavior (EMG, NCS), functional tests (walk, balance, strength), and patient-reported fatigue, pain, and quality of life. Strict safety monitoring and exclusion criteria are in place. This study will provide preliminary data on WB-EMS as a potential exercise modality for NMD.",[98,99,100,101,102,103,104,105,106,107,108,109,110,27,111,112,113,114],"Neuromuscular Diseases (NMD)","Amyotrophic Lateral Sclerosis","Myasthenia Gravis","Lambert-eaton Myasthenic Syndrome","Primary Lateral Sclerosis","Spinal Muscular Atrophy","Charcot Marie Tooth Disease (CMT)","Fascioscapulohumeral Muscular Dystrophy","Inclusion Body Myositis","Mitochondrial Myopathy","Nemaline Myopathy","Centronuclear Myopathy","Postpolio Syndrome","Chronic Inflammatory Demyelinating Polyneuropathy","Hereditary Spastic Paraplegia","Postural Orthostatic Tachycardia Syndrome (POTS)","Progressive Muscular Atrophy",[38,116,117,118],"Electrical Stimulation","Whole Body stimulation","Exercise intervention","2026-03-12",{"date":121,"type":47},"2026-03-17",{"date":123,"type":47},"2026-03-10",{"date":125,"type":20},"2031-01-07",{"name":127,"class":128},"University of Missouri-Columbia","OTHER",1,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":129},"100546192","phase-1-evaluation-of-the-safety-and-efficacy-of-late-onset-pompe-disease-gene-therapy-drug-100546192","NCT06391736","Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug","A Multi-centered, Single Arm, Open Labeled, Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector Expressing the Human Acid Alpha-glucosidase (GAA) Transgene Intravenous Injection in Patients With Late-onset Pompe Disease","Inclusion Criteria:\n\n* Age ≥ 6 years, males or females;\n* Patient has a diagnosis of LOPD;\n* Patient has upright FVC ≥ 30% of predicted normal value;\n* A 6MWT ≥ 40 meters, assistive device allowed;\n* The patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.\n\nExclusion Criteria:\n\n* Patient who has any history or concurrent clinical organic disease, including cardiovascular and liver diseases, respiratory system, nervous system disease, or any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study.\n* Patient who requires invasive mechanical ventilation, or rely on noninvasive non-non-invasive assisted ventilation when sitting upright;\n* Patient who is positive for human immunodeficiency (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody;\n* Patient with a history of glucocorticoid allergy;\n* Patient who has a contraindication to study drug or to corticosteroids, or has demonstrated hypersensitivity to any of the components of the study drug;\n* Patient who has AAV9 neutralizing antibody titer ≥ 1:100；\n* Patient who has participated in a previous gene therapy research trial;\n* Pregnant or lactating female participants;\n* Patients who have fertility plans within 6 months from screening to the end of the study and are unwilling to take effective physical contraceptive measures (such as a condom, intrauterine device, contraceptive ring, ligation, abstinence, etc.) for contraception (including the subject's partner);","6 Years",{"count":139,"type":20},33,[23,24],"This study is being conducted to evaluate the safety and effectiveness of GC301 adeno-associated virus vector expressing codon-optimized human acid alpha-glucosidase (GAA) as potential gene therapy for Pompe disease. Patients diagnosed with late-onset Pompe disease （LOPD） who are ≥ 6 years old will be studied.",[27],"2025-07-01",{"date":145,"type":47},"2025-07-03",{"date":147,"type":47},"2024-04-19",{"date":149,"type":20},"2026-12",{"name":151,"class":54},"GeneCradle Inc",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":160,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":163,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":4},"100560337","phase-4-treatment-frequency-reduction-in-pompe-disease-100560337","NCT06575829","Treatment Frequency Reduction in Pompe Disease","Open Label, Single-center Pilot Study to Investigate Alglucosidase Alfa (20 mg\u002Fkg) Frequency Reduction From 2 to 4 Weeks in a Subgroup of Elderly Patients With Late-onset Pompe Disease (TRIPOD-Study)","TRIPOD","Inclusion Criteria:\n\n* LOPD (confirmed diagnosis: enzyme deficiency in any tissue source and\u002For 2 confirmed disease-causing variants in the GAA gene)\n* Age ≥50 years\n* Current treatment with alglucosidase alfa at a standard dose of 20 mg\u002Fkg once every 2 weeks for ≥4 years\n* Relatively stable clinical condition over the past year\n* Able to walk ≥150 m within 6 minutes (6MWT)\n* (Forced) vital capacity (FVC) in sitting position: \\>55% of expected value and in supine position: \\>45% of expected value\n* Willing and able to adhere to the study procedures\n\nExclusion Criteria:\n\n* Rapidly progressive muscle weakness\n* Severely limited muscle strength almost requiring\u002Frequiring daily wheelchair use\n* Requiring respiratory support (non-invasive\u002Finvasive ventilation) or being at high risk to require respiratory support (ventilation) due to further deterioration of current pulmonary function. Using continuous positive airway pressure (CPAP) support only for obstructive sleep apnea syndrome (OSAS) is permitted.\n* Comorbidities which are expected to influence the primary outcome measures within the next 2 years","50 Years",{"count":162,"type":20},10,[164],"PHASE4","The aim of this study is to assess if dosing frequency reduction of alglucosidase alfa 20 mg\u002Fkg once every 2 weeks to once every 4 weeks is safe and does not lead to increased progression of disease in a selected group of patients with late-onset Pompe disease.",[27,167,168,34],"GAA Deficiency","Glycogen Storage Disease Type II","NOT_YET_RECRUITING","2024-08-26",{"date":172,"type":47},"2024-08-28",{"date":174,"type":20},"2024-10-01",{"date":176,"type":20},"2027-12-31",{"name":178,"class":128},"Erasmus Medical Center",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":21,"phases":187,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":169,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":129},"100529796","early-phase-1-evaluation-of-the-safety-tolerability-and-efficacy-of-gene-therapy-drug-for-late-onset-pompe-disease-lopd-100529796","NCT06178432","Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)","A Single-arm, Open-label, Single-dose Study to Evaluate the Safety, Tolerability, and Efficacy of CRG003 Injection in the Treatment of Late Onset Pompe Disease","Inclusion Criteria:\n\n1. Participants voluntarily sign informed consent form;\n2. Clinically diagnosed with LOPD;\n3. Males or females aged ≥ 18 years;\n4. Undergone enzyme replacement treatment (ERT) with recombinant human acid alpha-glucosidase (rhGAA) previously, and has been discontinued for at least four weeks before screening;\n5. Acceptable Pulmonary test results;\n6. A 6MWT ≥ 100 meters, and ambulation for 40 meters without stopping and without an assistive device;\n7. Acceptable laboratory values;\n8. Acceptable GAA anti-drug antibody titer;\n9. Acceptable capsid antibody titers;\n10. Use of reliable contraception methods during the study;\n11. Participants with good compliance.\n\nExclusion Criteria:\n\n1. Severe cardiomyopathy was defined as left ventricular ejection fraction (LVEF) \\\u003C 45% or New York Heart Association (NYHA) functional class 3 or above;\n2. Require invasive mechanical ventilation, or rely on noninvasive ventilation during the day;\n3. Intolerance to ERT, prior experience of serious infusion-associated reactions (IARs), prior experience of serious allergic reactions or investigator-assessed intolerance to ERT;\n4. Have received any systemic immunosuppressants (except inhalation or topical use) other than glucocorticoids or investigator-recommended immunosuppressants 30 days prior to screening, and known intolerance to immunosuppressants such as glucocorticoids;\n5. Positive for hepatitis B surface antigen (HBsAg) or hepatitis B virus DNA (HBV-DNA), positive for hepatitis C virus RNA (HCV-RNA). Participants with a history of hepatitis B or C can be regarded as negative if both two samples collected at an interval of at least three months are tested negative for the above parameters; positive for human immunodeficiency virus (HIV) or positive serologic test for syphilis;\n6. Currently on antiviral therapy for hepatitis B or C;\n7. Have clinical organic diseases (except symptoms or diseases associated with Pompe disease), including active tuberculosis, cardiovascular and cerebrovascular diseases, hepatobiliary system, respiratory system, nervous system, urinary system, or endocrine system disorders (such as diabetes, etc.), or other serious complications, or other conditions that make the patients not eligible for the study according to the investigator;\n8. Have underlying liver diseases, e.g., prior diagnosis of portal hypertension, splenomegaly, hepatic encephalopathy, severe fatty liver, cirrhosis or liver fibrosis ≥stage 3; or ultrasound-identified liver neoplasms or laboratory tests suggesting elevated alpha-fetoprotein, etc., which are considered by the investigator as clinically significant;\n9. Have received gene therapy prior to screening or used other investigational drugs or drugs that affect this study as evaluated by the investigator within four weeks prior to screening or within 5 half lives of the investigational drug (whichever is longer);\n10. Have received or will receive any herbal preparations (herbal supplements or traditional Chinese medicines derived from plants, minerals, or animals, other than topical medications) that may affect liver function or Chinese herbal medicines that may affect the study as judged by the investigator four weeks prior to study medication or during the study follow-up period;\n11. Alcohol dependence or drug addiction, and inability to stop alcohol intake as ordered by the doctor during the study;\n12. Have received any live vaccine two months predose or history of vaccination within 30 days prior to screening or planning to receive vaccination during the screening and the main study period;\n13. Pregnant or lactating female participants;\n14. Other conditions that make the participants not eligible for the study according to the investigator.",{"count":5,"type":20},[188],"EARLY_PHASE1","This is a single-center, single-arm, open-label, single-dose treatment clinical study to evaluate the safety, tolerability and efficacy of CRG003 injection in participants with late onset Pompe disease (LOPD), with a long-term follow-up period of 5 years.\n\nCRG003 (BBM-G102) injection is an adeno-associated virus (AAV) gene therapy product for treating Pompe disease to stably express active GAA enzyme in the liver on a long-term basis after the injection.",[27],[29],"2023-12-20",{"date":194,"type":47},"2023-12-21",{"date":196,"type":20},"2023-12",{"date":198,"type":20},"2028-12",{"name":200,"class":128},"Huashan Hospital"]